OBR Daily Commentary

forumImage

20% Cut to NIH Budget Would Leave Americans More Vulnerable To Cancer And Other Diseases, Experts Warn

(Los Angeles Times) Mar 16, 2017 - A future in which cancers are cured, heart disease prevented and devastating brain disorders reversed may just have gotten a bit more distant, leaders of the nation’s leading biomedical research organizations said Thursday.

Dean Gesme, MD (Posted: March 17, 2017)

quotesSurely defending our country's medical health warrants expenditures as great as defending our country's borders from immigrants or foreign aggressors!quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Some Cancer Patients 'Hyperprogress' on Immunotherapy

(Medscape Medical News) Mar 9, 2017 - Although many people respond well to immunotherapy, some patients have cancers that appear to rapidly progress with treatment. Genomics could be the key to identifying these cases in advance.

H. Jack West, MD (Posted: March 10, 2017)

quotesWe still have more questions than answers about the potential for patients to "hyperprogress" after exposure to immunotherapies, but this has been reported elsewhere (Champiat, Clinical Cancer Res, 2016), and several clinical groups have reported that they have anecdotally noted this phenomenon at their centers, some even noting that they are working on preparing manuscripts that characterize it more fully. This concept will be critical to understand better, especially as immunotherapy moves earlier into and more broadly across treatment paradigms in many cancers.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

MedPAC Mulls Changes to Part B Drug Program

(MedPage Today) March 3, 2017 - The Medicare Payment Advisory Committee (MedPAC) says that the way physicians are paid for administering drugs under Part B of the Medicare program should be changed, but not all committee members agree on how that change should occur.

Winston Wong, PharmD (Posted: March 09, 2017)

quotesI am not sure that the consolidated billing for biosimilars is a good idea, mainly because these drugs are not interchangeable. Using a single consolidated J-code will imply that these drugs can be substituted for each other, and they are not. I am also concerned that using the WAC will eventually lead us back to the issue we saw with the inflated AWP.quotes

Read Article arrow
Add Comment 2 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Professor and Chair, Department of Radiation Oncology...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Health Policy
member photo
Joseph Bailes, MD

National Health Policy Expert...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Professor and Physician-in-Chief of the Ohios State Uni...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...